-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Migraine is a chronic disease with repeated mild or severe headaches, usually accompanied by various autonomic nervous system symptoms.
Associated symptoms may include nausea, vomiting, more sensitivity to light, more sensitivity to sounds, and physical activity can aggravate the feeling of pain.
One-third of migraine patients can feel the aura of symptoms: short-term visual, sensory, language, or physical impairment means that the headache is about to occur, which is called migraine with aura.
At present, it is generally believed that the cause of migraine is a combination of environmental factors and genetic factors.
Nearly 70% of patients have genetic factors.
Prevention 43% of migraine prophylactic medication patients have a history of medication failure or drug replacement.
Basic research has found that calcitonin gene-related peptide (CGRP) substances have been shown to participate in the occurrence of migraine by expanding blood vessels in the brain .
Calcitonin gene-related peptide (CGRP) substances have been shown to be involved in the occurrence of migraine by expanding blood vessels in the brain .
The patients were randomized to receive a placebo or gallanizumab (120 mg per month for 3 months) at a 1:1 ratio.
During the period 2018.
In general, the number of migraine days in patients treated with gallanizumab was significantly reduced in 1-3 months compared with placebo.
Compared with the baseline, the number of migraine days per month in the galantizumab group was reduced by an average of 4.
The number of migraine days per month in the gallanizumab group was reduced by an average of 4.
In summary, this study shows that galantizumab is safe and effective for patients with paroxysmal migraine or chronic migraine.
references:
references:Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Leave a message here
